Hikma intros furosemide injection

Hikma has launched furosemide injection, in 20mg/2ml, 40mg/4ml, 100mg/10ml,  500mg/50ml and 1,000mg/100ml presentations. 

“Hikma is introducing the first FDA approved 50ml and 100ml presentations to the U.S. market and we are pleased to expand our portfolio with this launch, broadening the choice of medicines available to hospitals,” the company said.

[Read more: Hikma intros Kloxxado]

Furosemide injection is indicated in adults and pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. It is also indicated as adjunctive therapy in acute pulmonary edema.

Furosemide injection, 20mg/2ml, 40mg/4ml and 100mg/10ml had a market value of  approximately $30 million in the 12 months ending September 2024, per IQVIA.

[Read more: Hikma enters Spanish generic injectables market]